Monocyte and dendritic cell (DC) development was evaluated using in vivo BrdU pulse-chase analyses in rhesus macaques, and phenotype analyses of these cells in blood also were assessed by immunostaining and flow cytometry for comparisons among rhesus, cynomolgus, and pigtail macaques, as well as African green monkeys and humans. The nonhuman primate species and humans have three subsets of monocytes, CD14 
CD16
+ cell subset. The differentiation kinetics of BDCA-1 + myeloid DC and CD123 + plasmacytoid DC were distinct from the monocyte subsets, indicating differences in their myeloid cell origins. Results from studies utilizing nonhuman primates provide valuable information about the turnover, kinetics, and maturation of the different subsets of monocytes and DC using approaches that cannot readily be performed in humans and support further analyses to continue examining the unique myeloid cell origins that may be applied to address disease pathogenesis mechanisms and intervention strategies in humans. The Journal of Immunology, 2015, 195: 000-000.
B lood monocytes and dendritic cells (DC) are bone marrow-derived leukocytes involved in innate immune responses to infection (1). Monocytes arise from myeloid
progenitors within bone marrow, migrate into the blood circulation, and may be induced to leave the circulation for differentiation into tissue macrophages and DC. In humans, three subsets of monocytes have been identified by differential expression of CD14 and CD16 (2, 3) . Classical monocytes constitute the majority of monocytes in healthy individuals, and are strongly positive for CD14 and negative for CD16 (CD14   +   CD16 2 ). Intermediate monocytes express high levels of both CD14 and CD16 (CD14 + CD16 + ), and the nonclassical monocytes express low levels of CD14 and high levels of CD16 (CD14 2 CD16 + ). Monocytes expressing CD16 account for only 5-15% of all monocytes during homeostasis, but increase significantly during infectious diseases and inflammatory disorders (4) (5) (6) .
Two functional populations of blood DC have been described and include myeloid DC (mDC) and plasmacytoid DC (pDC) based on precursor cells of origin (7, 8) . Blood DC and monocytes express HLA-DR and are distinct from the leukocyte lineage cell fraction, but there is still confusion in clearly delineating DC subsets from monocytes due to a lack of specific cell surface markers (9) . CD11c, for example, is often considered one of the myeloid DC markers, but it is also expressed at highest density on blood monocytes and at moderate levels on granulocytes in humans and mice (10, 11) . In addition, the CD14
2

CD16
+ monocytes in humans are currently classified as nonclassical monocytes, but this population overlaps with CD16 + mDC using a previously reported blood DC gating strategy (12) . Currently, human blood DC populations are defined by their lineage and expression of blood DC Ags (BDCA) (3) . The pDC are identified by expression of BDCA-2 (CD303), whereas the mDC can be further subdivided by differential expression of either BDCA-1 (CD1c) or BDCA-3 (CD141) (3).
Nonhuman primates (NHP) are genetically and physiologically closely related to humans, and thus serve as valuable models of human diseases and immune responses (13) . An added advantage is that many Abs to human monocytes, macrophages, and DC exhibit cross-reactivity to these cells from rhesus macaques (14, 15) . In earlier studies, we successfully demonstrated that in vivo BrdU pulse-chase experiments could be applied to monitor changes in the turnover rates of blood monocytes during viral and bacterial infections in rhesus macaques that were predictive for disease outcomes (16, 17) . BrdU, a thymidine analog, incorporates into hematopoietic progenitor cells possessing proliferating capacity in bone marrow, and thus can be used as a tool to characterize differentiation of myeloid lineage cells in vivo. The purpose of this study therefore was to characterize the phenotype, turnover, and differentiation of monocytes and DC in rhesus macaques to expand our knowledge of the biology of myeloid cell development in humans. Such information is difficult to monitor longitudinally in humans, and the results from studying rhesus macaques will contribute to better understanding mechanisms of disease pathogenesis and development of immune responses produced by monocytes, macrophages, and DC in humans.
Materials and Methods
Nonhuman primates
Rhesus macaques (Macaca mulatta), cynomolgus macaques (Macaca fascicularis), pigtail macaques (Macaca nemestrina), and African green monkeys (Chlorocebus sabaeus) were housed at the Tulane National Primate Research Center and were sampled for blood samples used in this study. In addition, blood was obtained from a set of rhesus macaques infected with 300 tissue culture-infective dose 50 units of SIVmac239 i.v. and treated with s.c. inoculations of combination antiretrovirus therapy (cART) that comprised 20 mg/kg tenofovir dispoproxil fumarate once daily and 40 mg/kg Lamivudine (3TC) once daily, a gift of Gilead, for Ag-specific cell proliferation assay. Animal facilities, husbandry, and procedures were approved by the Institutional Animal Care and Use Committee of Tulane University in compliance with the standards of the Association for Assessment and Accreditation of Laboratory Animal Care and the Guide for the Care and Use of Laboratory Animals prepared by the National Research Council.
Blood specimens and BrdU administration to measure cell turnover
Rhesus macaques were injected with the thymidine analog, BrdU, i.v. at a dose of 60 mg/kg body weight, and EDTA anticoagulated blood samples were collected at varying times after administration, as indicated in Results. BrdU incorporation to measure cell turnover rate was determined by Ab staining and flow cytometry. Blood from cynomolgus macaques, pigtail macaques, and African green monkeys was only used for phenotype analyses in this study.
Healthy human EDTA anticoagulated blood samples were obtained from Research Blood Components (Boston, MA).
Flow cytometry
Blood specimens collected in EDTA anticoagulant were washed once with at least 5 vol PBS containing 2% FBS in PBS (2% FBS-PBS) and resuspended in the original volume of 2% FBS-PBS. Fresh blood specimens were stained for the evaluations in this study. There was negligible nonspecific background staining, so the live/dead marker stain was not used in this work. Two hundred microliters of washed blood were stained for expression of surface markers by incubation with Abs for 20 min at room temperature (see Table I for list of Abs). RBCs were lysed with 13 FACS lysing solution (BD Biosciences), and the remaining cells were permeabilized using a three-step incubation procedure with Cytofix/Cytoperm (BD Biosciences) for 20 min, Perm/Wash buffer (BD Biosciences) supplemented with 10% DMSO to boost permeabilization for 10 min (18) , and Cytofix/Cytoperm for 5 min. For analysis of BrdU incorporation, cells were incubated with anti-BrdU Ab for 20 min at room temperature after 1-h incubation at 37˚C with DNase I (Roche Diagnostics). After washing, all sets of cells were fixed with PBS containing 1% paraformaldehyde (Electron Microscopy Systems), acquired with a LSR II flow cytometer (BD Biosciences), and analyzed for cell surface phenotype using FlowJo software version 9.6 (Tree Star). Live/Dead marker was not used in this study.
Ag-specific cell proliferation assay PBMC were enriched by Ficoll gradient centrifugation of blood obtained from rhesus macaques chronically infected with SIVmac239 and undergoing cART. These animals that controlled plasma viral loads ˂1000 copies/ml and exhibited normal monocyte turnover and phenotype (data not shown) were selected for this study because they expressed SIVspecific cell proliferation and immune responses. Monocytes, DC subsets, and CD3 + T cells were sorted by flow cytometry using the BD FACS Aria (Fig. 1) . Each monocyte and DC population was incubated for 2 h with SIVmac251 Gag PR55 protein (National Institutes of Health AIDS Research and Reference Reagent Program) for stimulating Ag-specific CD3 + T cell proliferation ex vivo. After washing with RPMI 1640 supplemented with 10% FBS, 10,000, 5,000, and 2,500 cells of Gag-pulsed monocytes or DC subsets were cultured with 1 3 10 5 CD3 + T cells in a 96-well U-bottom culture plate for 4.5 d. Another thymidine analog, 5-ethynyl-29-deoxyuridine (EdU), was added at a final concentration of 10 mM during the last 18 h of the culture, and cell proliferation was detected as a function of EdU incorporation using the Click-iT EdU Flow Cytometry Assay Kit (Life Technologies). Results were acquired using a FACS Verse flow cytometer (BD Biosciences), and data were analyzed by FlowJo software.
Statistical analyses
Mann-Whitney rank test was used to compare the mean differences between groups using Graphpad Prism version 5.0f for Mac (GraphPad Software, San Diego, CA). The p value ,0.05 was considered statistically significant.
Results
Blood monocyte and DC subpopulation phenotypes are similar in rhesus macaques and humans Blood monocytes and DC subsets from rhesus macaques and humans were evaluated by multicolor flow cytometry using previously described panels of Abs to phenotypic markers (3, 14, 15) and as shown in Table I and Fig. 1 . Because monocytes and DC are considered myeloid lineage cells, HLA-DR-positive and lymphocyte/NK marker-negative cells were gated to further characterize monocytes and DC. Although CD56 is a common NK marker in humans, it also is expressed on monocytes in rhesus macaques (19) . Thus, CD8 was used instead of CD56 to discriminate NK cells in rhesus macaques. NKG2A or NKp46 was not applied to further exclude NK cells because most NKG2A-positive cells are HLA-DR negative or CD8 positive. Therefore, these HLA-DR-positive and lymphocyte/NK lineage markernegative cells contained negligible numbers of NK cells (data not shown). As reported previously, four distinct populations of cells could be distinguished based on CD14 and CD16 expression on HLA-DR-positive, lymphocyte/NK lineage marker-negative cells in both humans and rhesus macaques (7, 20) (Fig. 1 ). Of these four populations, three were identified as monocyte subsets Figs. 1, 2) . The CD16 + population previously identified as a DC subset is recently classified instead as a subset of monocytes (3) . Therefore, Abs to BDCA-1, CD141, and CD123 markers were used to identify three DC subsets in humans (BDCA-1 + , CD141 + , and CD123 + DC) (Fig. 1A) , and only two DC subsets have been identified in rhesus macaques due to the lack of a reliable rhesus CD141-specific Ab (Fig. 1B, Table II) . By careful analysis of the three distinct DC subsets in human blood, we observed a CD141 + DC subset that The Journal of Immunologyexpressed CD11c, but was negative for CD16 and BDCA-1 and did not overlap with any of the other positive subsets of DC (Fig. 1A) . The rhesus cell subset that was negative for CD16 and BDCA-1 within the HLA-DR-positive, but lineage marker-negative cell fraction of cells (i.e., negative for CD3, CD20, CD8, CD16, and CD14) may include the rhesus homologous CD141 + cells. Therefore, the CD123 2 BDCA-1 2 fraction of rhesus cells and the equivalent fraction from human samples were compared with assessed proportions of monocyte and DC subsets (Fig. 2) . In both humans and rhesus macaques, similar patterns were observed. Over 70% of the HLA-DR-positive, lymphocyte-lineage marker-negative cells were CD14 + monocytes, and ,10% of the cells comprised a subset of DCs. Statistically significant differences in the mean percentage of HLA-DR-positive, lymphocyte lineage-negative subsets, however, were observed between human and rhesus macaque blood DC subsets. Specifically, levels of BDCA-1 + DC and BDCA-1 2
CD123
2 DC cell populations were higher in rhesus macaques, whereas CD123 + pDC numbers were lower in rhesus macaques compared with humans. No significant difference was observed in the monocyte subset levels between humans and rhesus macaques (Fig. 2A) .
Comparative expression of CD11c on monocytes and DC in human and nonhuman primate blood CD11c is considered a mDC marker in humans and mice and also has been widely used to identify mDC in rhesus macaques (3, 12, 21) . After detailed characterization of the different DC subsets shown in Fig. 1 and Supplemental Fig. 1 , it became apparent that myeloid DC subsets, as well as monocyte subsets, were positive for CD11c expression in humans, whereas only monocytes expressing CD16 (nonclassical monocytes) were positive for CD11c expression in rhesus macaques. Thus, relatively few DC were included within the CD11c + blood cell fraction in rhesus macaques. Because anti-human Abs are generally used for NHP studies, these differences in staining patterns could result from differences in levels of cross-reactivity. Therefore, we tested rhesus macaque blood specimens with two different mAb clones (S-HCL-3 and 3.9) for detecting CD11c and observed that cells incubated with clone 3.9 did not exhibit staining by S-HCL-3 in some rhesus macaques (data not shown). To further confirm whether this CD11c staining pattern is specific for rhesus macaques, we analyzed blood from other nonhuman primate species, including cynomolgus macaques (n = 11), pigtail macaques (n = (Fig. 3) . To maintain consistency, the same staining and flow cytometer setting conditions were used for all NHP samples analyzed in these studies. PBMC of pigtail macaques demonstrated CD11c staining of some cells within the CD14 + subset, but the rhesus macaque staining pattern for CD11c was similar to that of cells from cynomolgus and African green monkeys (Fig. 3) .
To confirm that the monocyte/DC classification using CD14 and CD16 expression in rhesus macaques is comparable to humans, with the exception of CD11c staining patterns, we performed a functional assay to compare the ability of the three rhesus cell populations, CD14 + CD16 2 , CD14 2 CD16 + , and CD14 2 CD16 2 , to present a recall protein Ag to T cells, as reported earlier for human monocyte/DC subsets (22) . The cell populations obtained from immune-competent rhesus macaques (n = 5) infected with SIVmac239 and administered cART were evaluated for their ability to respond to SIV Gag PR55. These animals exhibited normal monocyte turnover rate and phenotype of monocytes and DC when the assay was performed. Similar to the reported data in humans (22) (Fig. 4) .
Nonclassical CD14
2 CD16 + monocytes differentiate from classical CD14 + CD16
2 monocytes that originated from bone marrow Incorporation of BrdU following injection has been used to successfully track the fate of CD14 + (classical monocytes) in rhesus macaques (16) . To further investigate the origin and differentiation of the monocyte and DC subsets, blood samples were collected from four rhesus macaques between days 0 and 21 after BrdU injection to follow the kinetics of BrdU incorporation by myeloid cells using flow cytometry (Fig. 5) cells gradually decreased after day 7 until no BrdU staining cells were observed 21 d after injection (Fig. 5B) . We also followed the kinetics of BrdU incorporation into each subset of monocytes and DCs based on the gating strategy described in Fig. 1 , and the results chronicle the development of each cell subset after emigration from the bone marrow to blood and subsequent transition to tissues (Fig. 6) (Fig. 6A) . At that time, no BrdU staining was observed in the classical or intermediate monocyte subsets (Fig. 6) . These results indicate that CD14 + CD16
2 classical monocytes are continuously generated from bone marrow and that there is a steady-state differentiation from intermediate to nonclassical monocytes. In contrast to the monocyte subsets, two of the DC subsets identified in rhesus macaques, BDCA-1 + mDC and CD123 + pDC, showed distinct kinetics of BrdU incorporation (Fig. 6) . The BDCA-1 + mDC showed the fastest turnover and exhibited peak BrdU labeling within the first 24 h. BrdU incorporation peaked after 4 d in the CD123 + pDC subset, and the decline or loss of BrdU occurred more slowly than the decline observed for the other monocyte or DC subsets (Fig. 6) . These results imply that the two DC subpopulations of cells originate from distinct cells in the bone marrow and develop independently from monocyte differentiation (Fig. 7) .
Discussion
Nonhuman primates are physiologically similar to humans and thus serve as important animal models to better understand the human immune system. In this study, we compared the phenotype of blood monocytes and DC in nonhuman primates, particularly in rhesus macaques, with the phenotype of equivalent cells in human blood. Using our results and recommendations of the Nomenclature Committee of the International Union of Immunological Societies, we attempted to develop concordant classifications (3) that can be assigned to the cell subpopulations in rhesus macaques and determined the proportions of monocyte and DC subsets that reside in the HLA-DR-positive and lymphocyte (T, B, and NK cells) lineage-negative cell fractions (Figs. 1, 2 + pDC, described for humans, were also represented in rhesus blood (Fig. 1) . Despite the lack of clearly identifiable CD141 + mDC in rhesus blood, our overall results are consistent with previous reports (4, 14, 15) .
The results in this study further examined additional relationships between human and rhesus macaque blood myeloid cell phenotypes (Fig. 1) . For example, mDC in rhesus macaques have been analyzed by the use of the CD11c marker on HLA-DR + lymphocyte lineage (CD3, CD20, CD8, and CD14) markernegative cells (Supplemental Fig. 2 ). This conventional mDC population includes a large proportion of nonclassical monocytes defined by the expression of CD16. This is most likely attributed to the differences between humans and nonhuman primates regarding expression of CD11c (Fig. 3, Supplemental Fig. 2 
CD8
2 cell population was examined by immunostaining and flow cytometry.
Because monocytes and DC displayed slightly distinct scatter plots, the cell population first was gated on HLA-DR, CD20, CD3, and CD8, and then the scatter plot was confirmed. The Journal of Immunologya mDC subset. Furthermore, the Ag presentation assay comparing the monocyte and DC subsets in rhesus macaques was functionally similar to results reported for these subset populations in humans, namely that the CD14 2 CD16 2 fraction containing BDCA-1 + mDC and CD123 + pDC induced Gag pr55 proteinspecific T cell proliferation, whereas the CD14 + CD16 2 (classical monocytes) and CD14 2 CD16 + (that had been classified as CD11c + mDC) did not present Ag to induce T cell proliferation (Fig. 4) (22) . These results thus suggest that the expression of CD11c for characterization of mDC in NHP needs to be reconsidered. A concern, however, is that we cannot conclude that CD14 + CD16 2 monocytes and BDCA-1 + mDC in NHP do not express CD11c because the human-specific Ab to CD11c either does not cross-react well to rhesus CD11c or this marker is not expressed by nonhuman primate blood cells. Examination of CD11c expression by nonhuman primate monocytes using gene expression analysis may help answer this question. CD141
+ DC in humans were identified within the CD123/BDCA-1 doublenegative fraction of the HLA-DR + lineage marker-negative (CD3 2 , CD20 2 , CD8 2 , CD16 2 , and CD14 2 ) cells (Fig. 1) , and the unidentified CD123/BDCA-1 double-negative cells within the CD14 2 CD16 2 fraction in rhesus macaques exhibited distinct kinetics of BrdU incorporation from other DC subsets (Fig. 6 ).
These results imply that additional DC subsets homologous to the CD141 + DC in human blood exist in nonhuman primate blood (Fig. 7) .
BrdU, a thymidine analog, is incorporated during DNA synthesis at the S-phase of cell cycle and is considered a reliable marker of dividing cells (23) (24) (25) . In vivo BrdU pulse-chase studies thus are useful for tracing the development, kinetics, trafficking, and turnover of replicating cells of the immune system in animal models (17, (26) (27) (28) (29) . Results presented in this work indicate that division of monocytes occurs at the hematopoietic stem cell-derived progenitor stage with myeloid-restricted differentiation potential in bone marrow, and that monocytes are then released into the circulation at the end of S-phase (30) . Although less information has been reported about the development and maturation of blood DC, our results shown in Figs. 5 and 6 directly support previous findings that the CD14
2
CD16
+ cells derived from a fraction of monocyte subsets were clearly distinct from the mDC subsets (22, 31 2 CD16 + cell subset as they gradually exhibit decreased expression of CD14 protein while circulating in blood. Our studies using BrdU pulse-chase analyses in rhesus macaques thus directly demonstrated a link in the differentiation and turnover among the three monocyte subsets and corroborate previous studies linking the developmental relationship among three monocyte subsets using M-CSF treatment in humans and NHP (32, 33) In vivo BrdU labeling of monocytes also has contributed to better understanding mechanisms of pathogenesis in infectious diseases (17, 26, 27, 29) . Because BrdU is considered carcinogenic, it has only rarely been applied in human studies (34) , so its use is more common in laboratory animals. For example, SIV infections in 
+ nonclassical monocytes in the circulation. The populations of mDC, pDC, and perhaps other unidentified DC appeared to differentiate from various DC precursors directly in the bone marrow prior entering the blood circulation.
NHP have served as useful models of HIV/AIDS, and we reported that an increasing monocyte turnover based on kinetics of BrdU labeling directly correlated with and predicted onset of terminal disease progression (26, 29, 35) . Similar observations regarding increased CD14 + monocyte turnover kinetics are lacking in HIVinfected humans despite expression of clinical signs (36) . This discrepancy, however, possibly could be investigated by applying continuous BrdU exposure in drinking water for humans instead of applying a single i.v. injection of BrdU as used in the NHP that would still enable labeling of the replicating cells to monitor turnover rate kinetics. Currently, however, these findings emphasize the usefulness of nonhuman primate models to study the kinetics of myeloid lineage cells as well as infectious disease pathogenesis in humans.
In this study, we also described distinct kinetics of BrdU labeling between BDCA-1 + mDC and CD123 + pDC that also differed from those of the monocyte subsets (Fig. 6) . BrdU-positive BDCA-1 + mDC peaked within the first 24 h and rapidly disappeared by 10 d, suggesting that they were derived rapidly from the bone marrow. By contrast, BrdU incorporation in CD123 + pDC only gradually increased during the first 4 d and slowly decreased over the subsequent 6 d, indicating a slower cell turnover than exhibited by the monocyte and BDCA-1 + DC subsets. The common DC progenitors in the bone marrow are strongly committed to produce both mDC and pDC, but they produce fewer pDC than mDC (37, 38) . Recently, a novel distinct DC-restricted precursor that produces pDC predominantly has been reported (8) , and the differences in kinetics and cell turnover between BDCA-1 + mDC and CD123 + pDC described in this study also suggest that they may originate from distinct progenitors. CD14 + monocytes are known to differentiate into monocyte-derived DC with many characteristics similar to mDC, so monocytes have been considered to be DC precursors. Our data suggest, however, that monocyte subsets did not give rise to any known DC subsets in vivo based on the BDCA-1 + mDC exhibiting the highest turnover kinetics among the monocyte and DC subset populations of cells.
In summary, our results using in vivo BrdU pulse-chase analyses demonstrate a link between the three subsets of monocytes and the two major DC subsets based on immune staining and flow cytometry using the rhesus macaque nonhuman primate model (Fig. 7) . We observed that myeloid precursors gave rise to CD14 + CD16
2 classical monocytes, and that a large proportion of these classical monocytes rapidly disappeared from the circulation to become tissue macrophages. A fraction of the classical monocytes differentiated into CD14 + CD16 + intermediate monocytes and then into CD14 2 CD16 + nonclassical monocytes during ∼10 d in circulation. It remains to be determined whether the monocytes in the intermediate fraction are simply classical monocytes differentiating into nonclassical monocytes or whether they comprise an independent cell subset that exists in the circulation. It also appears likely that mDC and pDC differentiate from different DC precursors and directly migrate from the bone marrow to the blood circulation. These findings could significantly enhance understanding of innate immune responses to infectious pathogens and the role of myeloid cells in infections and inflammation. . The DC populations traditionally described as mDC (blue dots) and pDC shown (red dots) were identified as CD14 -CD16 + and CD14 -CD16 -on monocyte gate, respectively (green arrows).
